Zerebrale MR-Bildgebung beim malignen Melanom

Clinical/methodical issueMelanoma is the third leading cancer entity to metastasize to the central nervous system (CNS) after lung and breast cancer. This is often an early event in the disease course and limits survival. Metastasis in the CNS is the cause of death in 10-40 % of melanoma patients an...

Full description

Saved in:
Bibliographic Details
Main Authors: Breckwoldt, Michael O. (Author) , Bendszus, Martin (Author)
Format: Article (Journal)
Language:German
Published: 16. Januar 2015
In: Der Radiologe
Year: 2015, Volume: 55, Issue: 2, Pages: 113-119
ISSN:1432-2102
DOI:10.1007/s00117-014-2761-0
Online Access:Verlag, Volltext: http://dx.doi.org/10.1007/s00117-014-2761-0
Verlag, Volltext: https://link.springer.com/article/10.1007/s00117-014-2761-0
Get full text
Author Notes:M. Breckwoldt, M. Bendszus

MARC

LEADER 00000caa a2200000 c 4500
001 1560234210
003 DE-627
005 20230428071254.0
007 cr uuu---uuuuu
008 170627s2015 xx |||||o 00| ||ger c
024 7 |a 10.1007/s00117-014-2761-0  |2 doi 
035 |a (DE-627)1560234210 
035 |a (DE-576)490234216 
035 |a (DE-599)BSZ490234216 
035 |a (OCoLC)1340976079 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a ger 
084 |a 33  |2 sdnb 
100 1 |a Breckwoldt, Michael O.  |d 1983-  |e VerfasserIn  |0 (DE-588)1022496298  |0 (DE-627)716993392  |0 (DE-576)365498297  |4 aut 
245 1 0 |a Zerebrale MR-Bildgebung beim malignen Melanom  |c M. Breckwoldt, M. Bendszus 
264 1 |c 16. Januar 2015 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 27.06.2017 
520 |a Clinical/methodical issueMelanoma is the third leading cancer entity to metastasize to the central nervous system (CNS) after lung and breast cancer. This is often an early event in the disease course and limits survival. Metastasis in the CNS is the cause of death in 10-40 % of melanoma patients and the incidence of brain metastasis is even higher (50-75 %). Cerebral metastases are commonly found in the subcortical white matter. The signal characteristics can vary substantially and may change over time due to hemorrhages or the accumulation of melanin and paramagnetic ions. It is not yet clear whether novel targeted therapies (e.g. immunotherapy and kinase inhibitors) alter imaging characteristics. Also immune-related side effects, such as hypophysitis (in approximately 5 % of patients receiving ipilimumab therapy) or granulomatous disease (neurosarcoid) can occur.Standard radiological methodsMelanoma metastases are usually hyperdense in computed tomography (CT). In magnetic resonance imaging (MRI) T2-weighted (T2-w) fluid-attentuated inversion recovery (FLAIR) and T1-w sequences (with and without i.v. contrast) should be obtained. Coronal and axial imaging planes should be scanned to cross-correlate findings.Methodical innovationsSusceptibility-weighted imaging is a new sensitive method to detect melanoma metastases. Approximately 66 % of melanoma metastases show intratumoral susceptibility signals (ITSS). This sets them apart from other metastases (e.g. lung and breast cancer show less ITSSs, specificity approximately 81-96 %). Diffusion imaging plays no major role in melanoma brain imaging.PerformanceSusceptibility-weighted imaging increases the sensitivity to detect metastases but lacks specificity. Differentiating metastases, microbleeding or calcification can be impossible. It is controversial how to interpret susceptibility signals without correlative signs on other sequences (differential diagnosis: metastasis, microbleeding and calcification).Practical recommendationsCNS metastases are common in melanoma. MRI screening starting in stage IIc should be considered even in asymptomatic patients. Stage IV requires quarterly MRI examinations. Melanotic and amelanotic metastases show different MRI characteristics. The differentiation between metastasis and microbleeding can be impossible and might require a follow-up scan. Susceptibility-weighted imaging increases the sensitivity of metastases detection but lacks specificity. It can help to differentiate between different metastatic entities. 
700 1 |a Bendszus, Martin  |e VerfasserIn  |0 (DE-588)1032676426  |0 (DE-627)738634131  |0 (DE-576)175567697  |4 aut 
773 0 8 |i Enthalten in  |t Der Radiologe  |d Berlin : Springer, 1996  |g 55(2015), 2, Seite 113-119  |h Online-Ressource  |w (DE-627)25463916X  |w (DE-600)1463036-9  |w (DE-576)074531832  |x 1432-2102  |7 nnas  |a Zerebrale MR-Bildgebung beim malignen Melanom 
773 1 8 |g volume:55  |g year:2015  |g number:2  |g pages:113-119  |g extent:7  |a Zerebrale MR-Bildgebung beim malignen Melanom 
856 4 0 |u http://dx.doi.org/10.1007/s00117-014-2761-0  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://link.springer.com/article/10.1007/s00117-014-2761-0  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20170627 
993 |a Article 
994 |a 2015 
998 |g 1032676426  |a Bendszus, Martin  |m 1032676426:Bendszus, Martin  |d 910000  |d 911100  |e 910000PB1032676426  |e 911100PB1032676426  |k 0/910000/  |k 1/910000/911100/  |p 2  |y j 
998 |g 1022496298  |a Breckwoldt, Michael O.  |m 1022496298:Breckwoldt, Michael O.  |d 910000  |d 911100  |e 910000PB1022496298  |e 911100PB1022496298  |k 0/910000/  |k 1/910000/911100/  |p 1  |x j 
999 |a KXP-PPN1560234210  |e 2972611128 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["M. Breckwoldt, M. Bendszus"]},"id":{"doi":["10.1007/s00117-014-2761-0"],"eki":["1560234210"]},"relHost":[{"pubHistory":["Volume 36, issue 1 (January 1996) [?]-volume 62, issue 5 (May 2022)"],"titleAlt":[{"title":"Zeitschrift für bildgebende Verfahren, Radioonkologie, Nuklearmedizin"},{"title":"Organ vom: Berufsverband der Deutschen Radiologen e.V."},{"title":"Organ der Arbeitsgemeinschaft Berufsverbände Medizinische Radiologie"}],"id":{"zdb":["1463036-9"],"issn":["1432-2102"],"eki":["25463916X"]},"part":{"volume":"55","year":"2015","text":"55(2015), 2, Seite 113-119","extent":"7","issue":"2","pages":"113-119"},"recId":"25463916X","physDesc":[{"extent":"Online-Ressource"}],"disp":"Zerebrale MR-Bildgebung beim malignen MelanomDer Radiologe","origin":[{"publisher":"Springer ; Springer","publisherPlace":"Berlin ; Heidelberg ; Berlin ; Heidelberg ; New York, NY","dateIssuedDisp":"[1996?-2022]"}],"title":[{"title_sort":"Radiologe","title":"Der Radiologe","subtitle":"Zeitschrift für diagnostische und interventionelle Radiologie, Radioonkologie, Nuklearmedizin : Organ des Berufsverbands der Deutschen Radiologen e.V."}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["ger"],"note":["Gesehen am 13.06.2022"]}],"person":[{"display":"Breckwoldt, Michael O.","role":"aut","given":"Michael O.","family":"Breckwoldt"},{"display":"Bendszus, Martin","given":"Martin","role":"aut","family":"Bendszus"}],"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"16. Januar 2015"}],"title":[{"title_sort":"Zerebrale MR-Bildgebung beim malignen Melanom","title":"Zerebrale MR-Bildgebung beim malignen Melanom"}],"note":["Gesehen am 27.06.2017"],"language":["ger"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1560234210","physDesc":[{"extent":"7 S."}]} 
SRT |a BRECKWOLDTZEREBRALEM1620